Key takeaways
- 503A pharmacies compound per prescription under lighter rules; 503B outsourcing facilities follow stricter batch-manufacturing standards.
- The FDA's drug shortage list, not general policy, is what legally opened compounding of tirzepatide and semaglutide copies.
- Several states now require compounding pharmacies to register, test for purity, or disclose raw material sourcing beyond FDA's floor.
- HPLC testing measures how much of a vial is your target peptide versus truncated or leftover synthesis byproducts.
- Endotoxin testing is a separate check from purity testing and both should appear on a real certificate of analysis.
In this article
State lawmakers are writing their own rulebooks for compounded GLP-1 drugs and peptides, stacking new requirements on top of whatever the FDA already demands. If you've followed the tirzepatide and semaglutide shortage story, this is the next chapter, and it says something useful about purity and sourcing that applies directly to the peptides sitting in your own freezer.
What "above the federal floor" actually means
A compounding pharmacy is a facility that mixes a drug to order rather than buying it pre-made from a big manufacturer. The FDA splits these into two types. A 503A pharmacy compounds for an individual prescription, under lighter oversight. A 503B "outsourcing facility" makes larger batches ahead of demand and has to follow stricter manufacturing rules closer to what a drug factory follows.
During the 2023-2024 shortage of brand-name tirzepatide and semaglutide, both drugs sat on the FDA's official shortage list. That listing is what legally opened the door for compounders to make copies. Once the FDA declared the tirzepatide shortage over in late 2024, that door mostly closed again for 503A pharmacies making exact copies.
States didn't wait for the FDA to sort out the rest. A number of state pharmacy boards have started adding their own layers: registration requirements for any pharmacy compounding peptides, mandatory purity testing before a batch can be dispensed, disclosure rules about where the raw material came from, and labeling standards. None of that replaces the FDA floor. It sits on top of it.
The chemistry problem underneath the politics
Peptides are short chains of amino acids linked together, built one link at a time in a lab synthesis process. That process almost never finishes perfectly. It leaves behind truncated chains that stopped forming too early, sequences with the wrong link inserted, and leftover solvent residue. None of that shows up by looking at a vial. It shows up on an HPLC trace, a test that separates a sample into its components and shows how much of what's in the vial is actually your target peptide versus everything else riding along with it.
There's a second, separate risk: endotoxins, which are fragments of bacterial cell walls that can survive even after the bacteria themselves are gone. A raw peptide powder made in a facility with poor process control can carry endotoxin contamination that a simple visual check will never catch. That's why a real certificate of analysis (COA) reports both a purity percentage from HPLC and a separate endotoxin result, not just one number.
State lawmakers pushing purity testing requirements onto compounding pharmacies are reacting to exactly this gap: a supply chain where "purity" was sometimes just a claim printed on a label rather than a number backed by a test.
What the research community gets wrong about all this
- An "RUO" or "research use only" label tells you nothing about purity by itself. It's a legal disclaimer about intended use, not a quality claim. Ask for the lot-specific COA.
- State compounding-pharmacy rules govern prescription pharmacies. They don't automatically apply to the separate supply chain that sells research peptides, so a state's new testing law doesn't mean your RUO vendor is covered by it.
- A peptide coming off the FDA shortage list changes who can legally compound it for a prescription. It has no bearing on whether that peptide is available, or well-made, through an RUO catalog.
- A purity number printed on a vial is only as good as the lab that generated it. Without an independent, dated COA showing the testing method, that number is a claim, not a result.
- Bulk raw peptide and a finished, tested product are not interchangeable in quality terms, even if the amino acid sequence is identical on paper.
What this means at your bench
Treat this regulatory shift as a preview of the standard your own sourcing should already meet. Request a lot-specific COA with every order, one that lists an HPLC purity result and an endotoxin result, not a generic spec sheet reused across batches. Reconstitute with bacteriostatic water rather than plain sterile water if your vial will be used across multiple sessions, since the added preservative keeps bacterial growth down over repeated draws. Keep reconstituted vials cold and shielded from light, and record the reconstitution date so you're not guessing at how long a vial has been open. None of that requires a new law. It just requires treating your own bench like the state boards are starting to treat compounding pharmacies.
Frequently asked questions
What's the difference between FDA rules and state rules for compounded peptides?
FDA sets a baseline through 503A and 503B compounding categories. States can add extra requirements on top, like mandatory purity testing, registration, or sourcing disclosure, that go beyond the federal minimum.
Do these state compounding laws apply to RUO peptide suppliers?
No. State compounding-pharmacy rules govern prescription pharmacies. Research-use-only chemical suppliers sit in a separate supply chain that isn't automatically covered by pharmacy board regulations.
How do I check the purity of a research peptide before using it?
Ask for a lot-specific certificate of analysis showing an HPLC purity percentage and a separate endotoxin test result. A label claim without a matching dated report isn't verified purity.
Prompted by this coverage at Google News →
Sources
- Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
- Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
- Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
✔ Reviewed by Bryan Le, PharmD, RPh
Bryan is a licensed pharmacist (Doctor of Pharmacy, Registered Pharmacist). Reconstituting lyophilized preparations is core pharmacy practice, so he reviews The Lab’s content for technical accuracy and to keep it within a research-and-education scope, with no medical or dosing advice. View profile on LinkedIn.
Related from our lab: the pen · cartridges · bacteriostatic water · reconstitution calculators
Shared by PreppinPeppers for research, educational, and demonstration awareness only. We link to third-party coverage; we do not endorse it, and nothing here is medical advice or a recommendation to use any substance in humans or animals. Our products are sold for laboratory research use only.
